Drug Trial Radar · NCT05963347
Go-CHOP as the Frontline Therapy for PTCL
Last checked: Nov 19, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
45
Planned (sponsor's estimate)
Start
Aug 3, 2023
Primary completion
Jul 30, 2025
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Conditions
- Peripheral T Cell Lymphoma
Interventions
GolidocitinibDrug
Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
CHOP RegimenDrug
CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: From first dose till 28 days post the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.